Healthcare Blog

As Genome Sequencing heads to $100 Direct-to-Consumer, a potential opportunity worth $50 Bn is expected to open up, leading to a million terabytes of genome data by 2025.

The genome sequencing market will reach $25 Bn by 2026, further intensified by COVID-19, and oncology and rare disease diagnostics coupled with pan genome studies. Adjacent markets of data storage, high performance computing (HPC), lab automation, and AI are anticipated to see unlocking of a further $20 Bn.

Download PDF Brochure: https://www.marketsandmarkets.com/practices/pdfdownload.asp?p=genomics

According to MarketsandMarkets analysis,

$50 Bn of potential opportunity is opening up as genome sequencing heads to $100 direct-to-consumer, which was one of the most talked-about trends in 2021.

The global genomic studies and projects comprising advanced genetic sequencing is expected to drive better clinical decision-making in the coming years, presenting lucrative growth opportunities to NGS companies.

Additionally, the life sciences market is witnessing an increased adoption of AI, personalized healthcare, gene editing, etc., which is likely to disrupt the demand for genomics, in turn impacting the growth of the market.

The increasing demand for sequencing and bioinformatics in diagnostics is predicted to disrupt the demand for IVD over the next few years.

MarketsandMarkets is focused on high-growth, niche markets, such as AI in genomics, spatial genomics & transcriptomics, liquid biopsy, single-cell analysis, and related markets, providing a comprehensive understanding of the entire genomics ecosystem through the World’s First Market Intelligence Cloud, ‘KnowledgeStore’. It helps find blind spots in clients’ revenue decisions because of interconnections and unknowns that impacting clients and their client’s clients.

For more details, please visit: https://www.marketsandmarkets.com/practices/genomics-new.asp

As Genome Sequencing heads to $100 Direct-to-Consumer, a potential opportunity worth $50 Bn is expected to open up, leading to a million terabytes of genome data by 2025.

The genome sequencing market will reach $25 Bn by 2026, further intensified by COVID-19, and oncology and rare disease diagnostics coupled with pan genome studies. Adjacent markets of data storage, high performance computing (HPC), lab automation, and AI are anticipated to see unlocking of a further $20 Bn.

Download PDF Brochure: https://www.marketsandmarkets.com/practices/pdfdownload.asp?p=genomics

According to MarketsandMarkets analysis,

$50 Bn of potential opportunity is opening up as genome sequencing heads to $100 direct-to-consumer, which was one of the most talked-about trends in 2021.

The global genomic studies and projects comprising advanced genetic sequencing is expected to drive better clinical decision-making in the coming years, presenting lucrative growth opportunities to NGS companies.

Additionally, the life sciences market is witnessing an increased adoption of AI, personalized healthcare, gene editing, etc., which is likely to disrupt the demand for genomics, in turn impacting the growth of the market.

The increasing demand for sequencing and bioinformatics in diagnostics is predicted to disrupt the demand for IVD over the next few years.

MarketsandMarkets is focused on high-growth, niche markets, such as AI in genomics, spatial genomics & transcriptomics, liquid biopsy, single-cell analysis, and related markets, providing a comprehensive understanding of the entire genomics ecosystem through the World’s First Market Intelligence Cloud, ‘KnowledgeStore’. It helps find blind spots in clients’ revenue decisions because of interconnections and unknowns that impacting clients and their client’s clients.

For more details, please visit: https://www.marketsandmarkets.com/practices/genomics-new.asp

The study involved four major activities in estimating the current size of the hemato oncology testing market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and market sizing with industry experts across the value chain through primary research.

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study. According to the new market research report “Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) – Global Forecast to 2024″, published by MarketsandMarkets™, the Hemato Oncology Testing Market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8%. Browse in-depth TOC on “Hemato Oncology Testing Market“ 77 – Tables 29 – Figures 116 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877 Growth in this market is driven mainly by the rising prevalence of lymphoma & myeloma cancers, growing focus on personalized medicine, and increasing collaborations for developing assays. The services segment accounted for the largest share of the product & services segment in the Hemato Oncology Testing Market in 2018. Based on product & services, the market is segmented into assay kits and services. In 2018, the services segment accounted for the largest share of the product & services segment in the Hemato Oncology Testing Market. The large share of this segment can be attributed to the rising prevalence of hematologic cancers and increasing aging population. Availability of robust infrastructure and high-end equipment for conducting hemato oncology tests are the supporting factors for clinical laboratories segment Based on end-user, the Hemato Oncology Testing Market has been segmented into four types, i.e., clinical laboratories, hospitals, academic & research institutes, and other end-users. Other end-users include CROs and pharmaceutical & biotechnological companies. Clinical laboratories accounted for the largest share of the market in 2018. This segment is expected to grow at the highest rate in the coming years. This is mainly due to the presence of advanced diagnostic equipment such as analyzers and the presence of skilled professionals to perform these tests. North America accounted for the largest share of the Hemato Oncology Testing Market in 2018 North America accounted for the largest share of the Hemato Oncology Testing Market in 2018. The large share of this segment can primarily be attributed to the high incidences of hematologic cancer, aging population, awareness regarding advanced treatment methods, and the strong presence of industry players in the region. These trends are likely to drive market growth during the forecast period. Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=262472877 Some of the leading players in the Hemato Oncology Testing Market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US). Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting Browse Related Reports: Molecular Diagnostics Market by Application (Infectious Disease (Hepatitis, HIV), Oncology, Genetic Testing), Technology (PCR, DNA Sequencing & NGS), End User (Hospital/Academic Laborato https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html Companion Diagnostics Market by Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), Technology (PCR, IHC, NGS, ISH), End User (Pharmaceutical & Biopharmaceutical

The major factors that are expected to be driving thegenotyping assay marketare technological advancements and the decreasing prices of DNA sequencing. The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years. The objective of the report is to define, describe, and forecast the genotyping assay market size based on product & service, technology, application, end user, and region.

According to the new market research report “Genotyping Assay Market by Technology (PCR, Sequencing, Microarray, Electrophoresis, MALDI-TOF), Application (Pharmacogenomics, Diagnostic Research, Animal Genetics, Agricultural Biotechnology), and Product – Global Forecast to 2023“, published by MarketsandMarkets™, the Genotyping Assay Market is expected to reach USD 31.9 billion by 2023 from an estimated USD 11.8 billion in 2018, at a CAGR of 22.0%.

Browse in-depth TOC on “Genotyping Assay Market“

219 – Tables

53 – Figures

280 – Pages

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595

The major factors driving the growth of this market include technological advancements, the decreasing prices of DNA sequencing, and the increasing incidence of genetic diseases.

By product, the reagents & kits segment is expected to account for the largest share of the Genotyping Assay Market

Based on product, the market is divided into reagents & kits, genotyping services, instruments, and bioinformatics. The easy accessibility to a wide range of reagents and need for genotyping in various applications (such as assessing drug efficacy & safety, cutting down cost and time required for clinical development, personalizing the treatments for chronic diseases, and developing good breeds of animals and plants) have contributed to the high and repetitive consumption of reagents and kits as consumables in various genotyping applications.

Sequencing segment will witness the highest growth in the market, by technology

Based on technology, the Genotyping Assay Market is segmented into PCR, microarrays, sequencing, capillary electrophoresis, MALDI-TOF, and other technologies. The sequencing segment is expected to account for the largest share of the global genotyping market during the forecast period of 2018 to 2023. The large share of this segment can be attributed increasing application areas of DNA sequencing technologies, technological advancements, the availability of high-speed sequencing instruments, the decreasing cost of DNA sequencing per genome, and the growing uptake of the hybrid approach of sequencing.

North America, the largest regional market for genotyping

North America is expected to account for the largest share of the Genotyping Assay Market in 2018, followed by Europe and the Asia Pacific. The increasing adoption of technologically advanced genotyping products, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, large number of genotyping-based R&D projects, and the presence of a large number of leading genotyping manufacturers in the region, along with an increasing demand from pharmaceutical companies for genotyping products and rising investments by government bodies, are responsible for the large share of the North American genotyping market.

Request for sample pages @https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595

The prominent players in the Genotyping Assay Market are Thermo Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).

Browse Adjacent Markets @ Biotechnology Market Research Reports & Consulting

Animal Genetics Market by Products & Services (Live Animals (Poultry, Porcine, Bovine, Canine) Genetic Material (Semen (Bovine, Porcine), Embryo (Bovine, Equine)) Genetic Testing (DNA Testing, DNA Typing, Genetic Traits Testing)) – Global Forecast to 2026

https://www.marketsandmarkets.com/Market-Reports/animal-genetic-market-12462093.html

High-Resolution Melting Analysis Market by Product (Supermix Reagent, RT PCR Instrument, Software), Application (SNP Genotyping, Mutation Discovery, Epigenetics), Enduser (Research Laboratories, Hospital, Diagnostic Center) – Global Forecast to 2021

https://www.marketsandmarkets.com/Market-Reports/high-resolution-melting-analysis-market-216456020.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly Singh

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]

According to a new market research report “Compound Management Market by Product & Outsourcing Services (Instruments (Automated Storage, Decapper), Software), Sample (Chemical Compounds, Biological Samples), End User (Biopharma Companies, Biobank, Pharma Companies, CRO) – Global Forecast to 2023“, published by MarketsandMarkets™, the global market is projected to reach USD 424.5 million in 2023 from USD 215.3 million in 2018, at CAGR of 14.5%.

Browse in-depth TOC on “ Compound Management Market “

95 – Tables

24 – Figures

118 – Pages

Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownload.asp?id=182172928

Increasing drug discovery activities, the growing biopharmaceutical industry, and the rising trend in outsourcing compound/sample management are the major factors driving the growth of the market.

Based on product and service, the outsourcing services segment is expected to grow at the highest CAGR in the market during the forecast period

On the basis of product & service, the market is broadly segmented into products (instruments & software) and outsourcing services. The outsourcing service segment is expected to grow at the highest CAGR in the global Compound Management Market. This can be attributed to the shift in trend towards outsourcing compound management to third-party service providers. These companies are experts in compound management and provide various services to pharmaceuticals, biopharmaceuticals, and CROs with regard to their compound storage needs, and are reasonably priced.

Based on sample type, the chemical compounds segment is expected to account for the largest share of the market in 2018

On the basis of sample type, the global Compound Management Market is divided into chemical compounds and biosamples. In 2018, the chemical compounds segment is expected to account for the largest share of the Compound Management Market. The rising drug discovery activity is leading to an increased demand for compounds which is positively affecting the market growth.

Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=182172928

North America is expected to account for the largest share of the market in 2018

Among the four geographic regions, North America is expected to account for the largest share of the Compound Management Market in 2018, followed by Europe, APAC, and the RoW. The large share of North America is attributed to the presence of the large pharmaceutical and biopharma industry. As a result, several companies in North America are engaged in drug discovery activities, which require maintenance of huge chemical libraries. Moreover, to maintain productivity of such innovative drugs and biologics, most of the leading pharma and biopharma companies have started building compound management facilities.

Market Players

The Compound Management Market is highly competitive due to the presence of a large number of players. Few companies that provide compound management systems are Brooks Life Sciences (US), Hamilton Company (US), TTP Group (UK), Labcyte (US), Biosero (US), and Tecan (Switzerland).

Browse Adjacent Markets @ Medical Devices Market Research Reports & Consulting

Lab Automation Market by Product (Robotic Arm, Microplate Readers, Workstation, LIMS, ELN), Application (Drug Discovery, Diagnostics, Genomics, Proteomics, Microbiology), End-User (Pharma, Diagnolab, Forensics, Environmental) – Global Forecast to 2025

https://www.marketsandmarkets.com/Market-Reports/lab-automation-market-1158.html

Laboratory Informatics Market by Type of Solution (LIMS, ELN, ECM, SDMS), Component (Software, Service), Deployment, Industry (Pharmaceutical, Biotechnology, Chemical, Agriculture, Petrochemical, oil & gas) – Global Forecasts to 2024

https://www.marketsandmarkets.com/Market-Reports/lab-informatic-market-203037633.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly Singh

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]

Market growth is driven by the global prevalence of infectious diseases & onset of COVID-19 and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements.

[263 Pages Report] The global infectious disease diagnostics market size is projected to reach USD 39.8 billion by 2026 from USD 28.1 billion in 2021, at a CAGR of 7.2%.

This study involved four major activities in estimating the current size of the infectious disease diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Market Dynamics

Global prevalence of infectious diseases and onset of COVID-19

Rising focus on R&D and funding in infectious disease diagnostics

Growing awareness for early disease diagnosis in developing countries

Rising technological advancements in infectious disease diagnostics

Shift in focus from centralized laboratories to decentralized POC testing

COVID-19 Impact on Global Infectious Disease Diagnostics Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (CHINA) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a matter of a few weeks. The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the infectious disease diagnostics market because of the use of infectious disease diagnostic methods for COVID-19 testing. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

Based on product & service, the infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. In 2020, the reagents, kits, and consumables segment accounted for the largest share of this market. The frequent purchase of these products due to their recurrent usage drives the market growth of this segment.

The infectious disease diagnostics market is segmented into immunodiagnostics, polymerase chain reaction (PCR), clinical microbiology, isothermal nucleic acid amplification technology (INAAT), DNA sequencing & NGS, DNA microarrays, and other technologies. In 2020, the immunodiagnostics segment accounted for the largest share. This can be attributed to the increasing use of immunoassays in COVID-19 testing, POC infectious disease testing, the development of novel immunodiagnostic tests, and the rising trend of automation.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Latin America5. Middle East & Africa

The global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global infectious disease diagnostics market. The North American infectious disease diagnostics market’s growth can be attributed to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments.

Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

Some key players mentioned in the research report are:

Abbott Laboratories (US)

Roche Diagnostics Ltd. (Switzerland)

bioMérieux SA (France)

Thermo Fisher Scientific Inc. (US)

According to the new market research report ” Drug Screening Market by Product (Consumables, Urine testing devices, Analytical, Breathalyzer, Chromatography) & Services, Sample Type (Urine, Breath), End User (Workplace, Laboratories, Criminal Justice, Hospitals) – Global Forecast to 2025″, published by MarketsandMarkets™ , global drug screening market is projected to reach USD 10.0 billion by 2025, from USD 4.5 billion in 2020, at a CAGR of 17.3%.

Major Growth Drivers:

Growth in this market is attributed to the rising drug & alcohol consumption, the enforcement of stringent laws mandating drug and alcohol testing, government funding in major markets, and regulatory approvals and product and service launches.

Expected Revenue Growth:

[192 Pages Report] The global drug screening market is projected to reach USD 10.0 billion by 2025, from USD 4.5 billion in 2020, at a CAGR of 17.3%.

COVID-19 impact on the drug screening market

COVID-19 has resulted in significant disruptions to businesses and economic activities globally and is expected to have a short-term negative impact on the drug screening market due to limited or non-availability of medical facilities/treatment centers, harm reduction service providers, and the fear of infection transmission. To reduce the strain on the healthcare system and decrease disease transmission, various governments worldwide provided guidelines to postpone or delay non-essential medical and surgical procedures.

Browse in-depth TOC on “Drug Screening Market”192 – Tables35 – Figures192 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773

The rapid testing devices segment will witness the highest growth during the forecast period.

Based on product, the drug screening market is segmented into analytical instruments, rapid testing devices, and consumables. Rapid testing devices market is further subsegmented into urine testing devices and oral fluid testing devices. The urine testing devices segment is expected to account for the largest market share in 2019. However, the oral fluid testing devices segment is projected to register highest CAGR during the forecast period. The high growth in this segment is attributed to the benefits it offers such as shorter detection window, non-invasive nature, and low risk of sample tampering.

North America was the largest regional market for drug screening market in 2019.

The drug screening market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America was the largest regional segment of the overall market, followed by Europe. The dominance of the North American market is attributed to factors such as rising consumption of illicit drugs, availability of government funding to curb drug abuse, and the presence of laws supporting drug screening, and growing burden of accidents due to unsafe levels of alcohol consumption.

Request for sample pages :  https://www.marketsandmarkets.com/requestsampleNew.asp?id=162987773

Key Market Players

What This Report Will Provide?

The biologics safety testing industry is constantly evolving with advancements in technologies and the development of new and improved safety testing programs across various industries. Highly skilled professionals are required to keep pace with the continuing changes in analytical technologies and safety testing methodologies.

Expected Revenue Growth:

[377 Pages Report] The global synthetic biology market size is projected to reach USD 30.7 billion by 2026 from USD 9.5 billion in 2021, at a CAGR of 26.5% during the forecast period.

Major Growth Boosters:

Factors such as a wide range of applications of synthetic biology, the rising R&D funding and growing initiatives in synthetic biology, declining cost of DNA sequencing and synthesizing, and increasing investments in the market are propelling the growth of this market. However, biosafety, biosecurity, and ethical concerns related to synthetic biology would hamper the growth of this market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=889

COVID-19 impact on the synthetic biology market

Many established pharmaceutical and biopharmaceutical companies, along with players of the synthetic biology market, have stepped forward to contribute to worldwide research efforts by providing synthetic biology for developing test kits, treatments, and vaccines to target the infection caused by the coronavirus. Synthetic biology is highlighted as one of the emerging technologies in a report from the European Parliament. It can fight the COVID-19 pandemic. The National Institute of Health in the US has also identified synthetic biology as one way to speed up vaccine development.

Recent Developments

In January 2021, Novozymes launched Frontia GlutenEx. It would help wheat processors increase their gluten protein recovery and, at the same time, cut down on energy consumption.

In February 2021, Merck partnered with BioNTech (Germany) to supply lipids for the production of Pfizer-BioNTech COVID-19 Vaccine (BNT162b2).

In January 2021, Merck acquired AmpTec (Germany). With this acquisition, the company strengthened its product portfolio to develop and manufacture mRNA for utilizing vaccines, treatments, and diagnostics.

Request for sample pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=889

Rising R&D funding and growing initiatives in synthetic biology

The R&D sector has conventionally remained capital-intensive due to long development periods and approval cycles. Governments recognize R&D as a crucial investment for the progress of any country, international competitiveness, and public benefit. Due to this, R&D expenditure and funding have witnessed a steady increase over the years. According to Business Wire (September 2020), the R&D spending on the life sciences industry surged 22% from 2018 to 2019.

Regional Growth Analysis:

This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global biologics safety testing market.

[185 Pages Report] The global biologics safety testing market is projected to reach USD 6.2 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 12.4% during the forecast period.

The growth of the global biologics safety testing market is driven by factors such as the growth in the biologics and biosimilars markets, growing concerns over cell culture contamination, and rising biopharmaceuticals R&D activities and investments. In addition, emerging markets and increasing biopharmaceutical outsourcing are expected to provide significant growth opportunities for players in the Biologics safety testing market.

Market Dynamics

Growth in the biosimilars and biologics markets

Growing concerns over cell culture contamination

Rising biopharmaceuticals R&D activities and investments

Emerging markets offer lucrative opportunities

Increasing biopharmaceutical outsourcing

Many companies are investing heavily in the development of biologics and biosimilars. Currently, more than half of the drug candidates in the discovery stage are biologics, such as proteins, peptides, and monoclonal antibodies. Biologics are expected to contribute around half of the revenue generated by the top 100 pharmaceutical products in the coming years.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144

Based on application, the biologics safety testing market is segmented into monoclonal antibodies manufacturing, vaccines manufacturing, blood and blood products manufacturing, cellular and gene therapy products manufacturing, and other applications. In 2020, the monoclonal antibodies manufacturing segment accounted for the largest market share. The large share of this segment can be attributed to the rising prevalence of diseases and increasing government initiatives for the development of monoclonal antibody drugs.

The geographical regions mapped in the report are:

This study involved four major activities in estimating the current autoinjectors market size. Exhaustive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the number of breast lesion localization procedures and the value market.

According to the new market research report “Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular Diseases, Diabetes), Type (Disposable, Reusable), Route of administration (Subcutaneous, Intramuscular), End User (Hospital) – Global Forecast to 2025″, published by MarketsandMarkets™, the Autoinjectors Market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025.

Browse in-depth TOC on “Autoinjectors Market”

99 – Tables

55 – Figures

180 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724

The Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

Diabetes segment is expected to show the highest growth in the forecast period.

The autoinjectors market, by therapy, is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, multiple sclerosis, and other therapies (includes cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). Diabetes mellitus, commonly known as diabetes, is a disease that arises from the insufficient production of insulin or the body’s inability to utilize insulin. To maintain healthy blood glucose levels, diabetes patients need a daily intake of insulin or Glucagon-like peptide-1 (GLP-1). This scenario will provide companies with abundant opportunities to develop innovative solutions and cater the end user’s demand.

Disposable autoinjectors accounted for the largest share of the autoinjectors market in 2020.

Based on type, the market is segmented into reusable and disposable autoinjectors. In 2019, the disposable autoinjectors segment accounted for the largest share of the global market. Disposable autoinjectors are the most-preferred autoinjectors due to their ease of use and the presence of a built-in glass syringe (eliminates the need of manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairment.

Home care settings segment accounted for the largest share and is expected to show the highest growth in the forecast period.

Based on end users, the autoinjectors market is segmented into home care settings, hospitals & clinics, and ambulatory care settings. Of all these end-user segments, home care settings accounted for the largest share of the market in 2019. The large share of this end-user segment can primarily be attributed to the rapid growth in the geriatric population across the globe and the growing need for cost-effective drug administration.

Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724

Asia Pacific is expected to witness fastest growth during the forecast period of 2020–2025.

Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is driven majorly by the large diabetes population and increasing healthcare expenditure in the regional countries have drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies

The prominent players in this market are AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany).

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting

Browse Related Reports:

Pen Needles Market by Type (Standard Pen Needles and Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, 10mm, 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) – Global Forecast to 2024

https://www.marketsandmarkets.com/Market-Reports/pen-needles-market-75948613.html

Wearable Injectors Market by Type (On-Body and Off-Body injectors (Infusion Pump Devices)), Therapy (Immuno-oncology, Diabetes, Cardiovascular diseases, Parkinson’s disease, Thalassemia, Primary Immunodeficiency Disease) – Global Forecast to 2023

https://www.marketsandmarkets.com/Market-Reports/wearable-injector-market-100771004.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’ flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/autoinjector-market.asp

Visit Our Web Site: https://www.marketsandmarkets.com

Market growth is driven by the rising prevalence of cancer, increasing cancer research, rising investments in regenerative medicine research, rising demand for monoclonal antibodies, and rapid growth in the biotechnology and biopharmaceutical industries.

According to the new market research report “Primary Cells Market by Origin (Human Primary Cells, Animal Primary Cells), Type (Hematopoietic, Dermatocytes, Gastrointestinal, Hepatocytes, Lung, Renal, Musculoskeletal, Heart), End User, Region – Global Forecast to 2025″, published by MarketsandMarkets™, the market is projected to reach USD 1,613 million by 2025 from USD 970 million in 2020, at a CAGR of 10.7% Browse and in-depth TOC on “Primary Cells Market” 108 – Tables 34 – Figures 179 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32854960 The Growth in this market is largely driven by the rising prevalence of cancer, increasing focus on the development of novel cancer therapies, and rising adoption of primary cells over cell lines. Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the Primary Cells Market. The human primary cells segment accounted for the largest share of the Primary Cells Market, by origin segment, in 2019 Based on origin, the Primary Cells Market is segmented into human and animal primary cells. The human primary cells segment accounted for the largest share in the Primary Cells Market in 2019. The growing application areas of human stem cells and the rising incidence of cancer are the major factors driving the growth of this segment. Hepatocytes segment to register the highest growth rate during the forecast period Based on type, the Primary Cells Market is segmented into hematopoietic cells, dermatocytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and other primary cells. In 2019, the hepatocytes segment accounted for the highest growth rate. This can be attributed to the increasing incidence of liver cancer & pediatric liver diseases across the globe, increasing research funding by key pharma players, and the emergence of new companies dedicated to liver therapeutics research. The life science research companies segment accounted for the largest share of the Primary Cells Market, by end user segment, in 2019 Based on end-users, the Primary Cells Market is segmented into life science research companies and research institutes. In 2019, the life science research companies segment for the largest share in the Primary Cells Market. Increasing cancer research in life science research companies, the increasing number of R&D facilities, high adoption of primary cells in cell-based experiments, and the increasing investments of companies in cell-based research are the major factors driving the growth of this segment. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=32854960 North America is the largest regional market for Primary Cells Market The Primary Cells Market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share in the Primary Cells Market. The growth in the North American Primary Cells Market can be attributed to increasing funding for cancer research, growing life science research sector, expansion of the healthcare sector, and the high adoption of stem cell therapy & cell immunotherapies for the treatment of cancer and chronic diseases. The major players operating in Primary Cells Market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics, Inc. (US), PromoCell GmbH (Germany), HemaCare Corporation (US), ZenBio, Inc. (US), STEMCELL Technologies, Inc. (Canada), Corning Incorporated (US), AllCells (US), American Type Culture Collection (US), Axol Bioscience Ltd. (UK), iXCells Biotechnologies (US), Neuromics (US), StemExpress (US), BioIVT (US), ScienCell Research Laboratories, Inc. (US), PPA Research Group, Inc. (US), Creative Bioarray (US), BPS Bioscience, Inc. (US), Epithelix Sàrl (Switzerland), ReachBio LLC (US), AcceGen (US), Sekisui XenoTech, LLC (US), and Biopredic International (France). Browse Adjacent

Factors such as increasing public and private funding for life science research, the significantly high prevalence of target diseases across the globe, and increasing R&D spending by pharmaceutical and biotechnology companies are expected to drive the growth of market.

According to a new market research report “Transfer Membrane Market by Type (PVDF, Nitrocellulose, Nylon), Transfer Method (Tank, Semi-dry, Dry), Application (Western, Northern, Southern Blot, Protein Sequencing), End user (Academia, Diagnolab, Pharmaceutical Companies) – Global Forecast to 2023“, published by MarketsandMarkets™, the global market is projected to reach USD 187.9 million by 2023 from USD 174.8 million in 2018, at a CAGR of 1.5% during the forecast period. Browse in-depth TOC on “Transfer Membrane Market“ 64 data 35 Figures 124 Pages Download PDF Brochure: @ https://www.marketsandmarkets.com/pdfdownload.asp?id=36975865 Factors such as increasing public and private funding for life science research, the significantly high prevalence of target diseases across the globe, and increasing R&D spending by pharmaceutical and biotechnology companies are driving the growth of this market. By Type, the PVDF transfer membrane segment is expected to hold the largest share of the market in 2018 On the basis of types, the Transfer Membrane Market is classified into nylon transfer membrane, nitrocellulose transfer membrane, and PVDF transfer membranes. In 2018, PVDF transfer membranes are expected to command the major share of the Transfer Membrane Market.. The PVDF transfer membrane segment is expected to account for the largest share of the Transfer Membrane Market in 2018. Advantages of PVDF transfer membrane over nitrocellulose membranes such as higher durability and hydrophobicity, increasing R&D by pharmaceutical and biotechnology companies, and growing proteomic research are the major factors driving the growth of this segment. By Transfer method, the dry electro transfer segment is expected to be the fastest growing segment in the forecast period On the basis of transfer method, the Transfer Membrane Market is segmented into tank electrotransfer, semi-dry electrotransfer, dry electrotransfer, and other transfer methods (diffusion blotting and vacuum blotting). The Dry electrotransfer segment is expected to grow at the fastest CAGR during the forecast period. Growth in this segment is attributed to the advantages of dry-electrotransfer over conventional methods, including rapid, high-quality transfer and ease of use due to the non-requirement of additional buffers in the case of dry-electroblotting. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=36975865 North America is expected to dominate the market in 2018 Geographically, the Transfer Membrane Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to account for the largest share of the market in 2018, followed by Europe. The large share of North America can primarily be attributed to presence of leading transfer membrane manufacturers in the region, availability of government and private financial support for life science research, and a high disease prevalence in the region. The key players in the Transfer Membrane Market include Merck KGaA (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), GE Healthcare (US), PerkinElmer (US), Pall Coporation (US), Advansta (US), GVS (Italy), Santa Cruz Biotechnology (US), Abcam (UK), ATTO Corporation (Japan), Carl Roth (Germany), Macherey-Nagel (Germany), Azure Biosystems (US), and Axiva Sichem Biotech (India), among others. Browse Adjacent Markets: Biotechnology Market Research Reports & Consulting Browse Related Reports: Western Blotting Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease Diagnostics), End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies) – Global Forecasts to 2021 https://www.marketsandmarkets.com/Market-Reports/western-blotting-market-235810711.html Membranes Market by Material (Polymeric, Ceramic), Technology (RO, UF, MF, NF), Application (Water & Wastewater Treatment, Industrial Processing), Region (North America, APAC, Europe, MEA, South America) – Global Forecast

The study involved four major activities to estimate the current market size for particle therapy. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter market breakdown and data triangulation was used to estimate the market size of segments and subsegments.

According to the new market research report “Particle Therapy Market by Type (Heavy Ion, Proton Therapy), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate, Breast), Application (Treatment, Research) – Forecast to 2023“, published by MarketsandMarkets™, the global Particle Therapy Market is projected to reach USD 1,349 million by 2023 from USD 865 million in 2018, at a CAGR of 9.3%.

Browse in-depth TOC on “Particle Therapy Market“

80 – Tables

36 – Figures

138 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12809137

The major factors driving the growth of the Particle Therapy Market are the growing global prevalence of cancer, growing adoption of particle therapy in clinical trials, advantages offered by particle therapy over photon therapy, and the increasing number of particle therapy centers worldwide.

The pediatric cancer segment is expected to account for the largest share of the Particle Therapy Market, by cancer type, in 2018

Based on cancer type, the Particle Therapy Market is segmented into pediatric cancer, prostate cancer, breast cancer, lung cancer, head & neck cancer, and other cancers. The pediatric cancer segment is expected to account for the largest share of the Particle Therapy Market in 2018. The growing incidence of pediatric cancer and the high success rates and minimal long-term risks achieved with particle therapy are the major factors driving the growth of this market segment.

Research applications to register the highest CAGR in the global Particle Therapy Market during the forecast period

Based on applications, the Particle Therapy Market is segmented into treatment applications and research applications. The research applications segment is expected to witness the highest CAGR during the forecast period. Growing awareness about the research applications of particle therapy systems, development of cost-effective and technologically advanced diagnostic and therapeutic particle therapy systems, and increasing industry-academia collaborations in the field of research are the key factors driving the growth of this segment.

Asia Pacific to dominate the Particle Therapy Market during the forecast period

The Particle Therapy Market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific region is expected to account for the largest share of the global Particle Therapy Market in 2018, and this trend is expected to continue during the forecast period. The Asia Pacific region is expected to offer significant growth opportunities for players operating in the Particle Therapy Market owing to the increasing healthcare expenditure and growing initiatives to promote the use of advanced particle therapy technologies in Asia Pacific countries.

Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=12809137

The major players operating in the Particle Therapy Market are Ion Beam Applications SA (Belgium), Varian Medical Systems, Inc. (US), Hitachi, Ltd. (Japan), Provision Healthcare (US), Mevion Medical Systems, Inc. (US), Sumitomo Heavy Industries, Ltd. (Japan), Optivus Proton Therapy, Inc. (US), ProTom International, Inc. (US), Advanced Oncotherapy plc (UK), and Danfysik A/S (Denmark).

Browse Adjacent Markets @ Medical Devices Market Research Reports & Consulting

Radiotherapy Market by Product (LINAC, CyberKnife, Gamma Knife, Tomotherapy, Particle Therapy, Cyclotron), Procedure (External (IMRT, IGRT, 3D-CRT) Internal (LDR, HDR)), Application (Prostate, Breast, Lung), End User (Hospitals) – Global Forecasts to 2026

https://www.marketsandmarkets.com/Market-Reports/radiotherapy-monitoring-devices-market-567.html

Patient Positioning System Market by Product (Tables (Surgical Tables, Radiolucent Imaging Tables), Accessories), Application (Surgery, Cancer Therapy, Disease Diagnosis), and End User (Hospitals, Ambulatory Surgery Center) – Global Forecast to 2022

https://www.marketsandmarkets.com/Market-Reports/patient-positioning-system-market-12586699.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly Singh

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]

This study estimates the market size for 2018 and projects its demand till 2023. Top-down and bottom-up approaches were used to validate the size of this market and estimate the size of other dependent submarkets. Various secondary sources such as directories, industry journals, databases (such as D&B Hoovers, Bloomberg Business, and Factiva), and annual reports of companies have been used to identify and collect information useful for the study of the oncology nutrition market.

According to a new market research report “Oncology Nutrition Market by Cancer Type (Head & Neck, Stomach & Gastrointestinal, Liver, Pancreatic, Esophageal, Lung, Breast, Blood) – Global Forecast to 2023“, published by MarketsandMarkets™, the market is expected to reach USD 2.21 Billion by 2023 from an estimated USD 1.46 Billion in 2018, at a CAGR of 8.7% during the forecast period.

Browse in-depth TOC on “Oncology Nutrition Market“

11 Tables

23 Figures

92 Pages

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=166703967

Objectives of the Study

To define, describe, segment, and forecast the oncology nutrition market for different types of cancer

To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, and industry-specific opportunities)

To forecast the size of the oncology nutrition market, in four main regions —North America (along with countries), Europe (along with countries), Asia Pacific, and the Rest of the World

To identify and profile key players in the global oncology nutrition market and comprehensively analyze their core competencies and market shares

To track and analyze competitive developments such as mergers and acquisitions; new product launches; expansions; collaborations and agreements; and R&D activities of the leading players in the global oncology nutrition market

Factors such as the shift from parenteral to enteral nutrition along with the increasing incidence of cancer, growing demand for nutritional feeding in the homecare sector, rising number of patients being treated for malnutrition, and increasing quality of clinical research on nutritional interventions are driving the growth of the Oncology Nutrition Market. Furthermore, the development of elemental formulas and product innovation in terms of non-GMO-based formulas present significant opportunities for the growth of excipients. However, the complications associated with tube feeding and limited reimbursements represent a significant challenge to the market growth.

By cancer type, the head and neck cancers segment accounted for the largest share of the market

On the basis of type of cancer, the head and neck cancers segment accounted for the largest share of the Oncology Nutrition Market, in 2017. This can be attributed to the use of tube feeding formulas for patients with head and neck cancers as conditions such as severe mucositis, xerostomia, dyspepsia, and nausea & vomiting in these patients limits nutritional intake.

Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=166703967

North America dominated the market in 2017

North America accounted for the largest share of the Oncology Nutrition Market in 2017, followed by Europe. This regional segment shows significant market growth owing to the increasing prevalence of chronic diseases and disorders, coupled with rapidly growing aging population, which shows greater susceptibility to chronic and acute disorders than other population segments. In addition, long-term care facilities such as homecare & hospices, nursing homes, and assisted living facilities have emerged as efficient alternatives to hospitals. Furthermore, owing to cost-cutting pressures in hospitals, the healthcare system has seen a shift from extended hospital treatment to treatment at home, which is expected to propel the demand for such feeding formulas.

The prominent players in the Oncology Nutrition Market are Abbott Laboratories (US), Nestle S.A. (Switzerland), Danone (France), Fresenius Kabi AG (Germany), and B. Braun Melsungen AG (Germany).

Browse Adjacent Markets @ Pharmaceutical Market Research Reports & Consulting

Enteral Feeding Devices Market By Type (Feeding Pump, Feeding Tube, Giving Set, Syringes), Age Group (Adult, Pediatric), Application (Oncology, Diabetes, Hypermetabolism), End User (Hospital, Home Care), COVID-19 Impact – Global Forecast To 2025

https://www.marketsandmarkets.com/Market-Reports/enteral-feeding-device-market-183623035.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Salgarkar

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441